Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

GTI-2040 displays cooperative anti-tumor activity when combined with interferon alpha against human renal carcinoma xenografts.

Vassilakos A, Lee Y, Viau S, Feng N, Jin H, Chai V, Wang M, Avolio T, Wright J, Young A.

Int J Oncol. 2009 Jan;34(1):33-42.

PMID:
19082475
2.

GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.

Lee Y, Vassilakos A, Feng N, Jin H, Wang M, Xiong K, Wright J, Young A.

Int J Oncol. 2006 Feb;28(2):469-78.

PMID:
16391803
3.

GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.

Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, Jin H, Xiong K, Liu C, Wright J, Young A.

Cancer Res. 2003 Jun 1;63(11):2802-11.

4.

Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.

Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, Attardo G.

Cancer Res. 1997 Nov 1;57(21):4803-10.

5.

Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.

Sato H, Senba H, Virgona N, Fukumoto K, Ishida T, Hagiwara H, Negishi E, Ueno K, Yamasaki H, Yano T.

Mol Carcinog. 2007 Mar;46(3):215-24.

PMID:
17186540
6.

A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.

Yuasa T, Nogawa M, Kimura S, Yokota A, Sato K, Segawa H, Kuroda J, Maekawa T.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):853-9.

7.

Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.

Tochizawa S, Masumori N, Yanai Y, Ohmoto Y, Yabuuchi Y, Tsukamoto T.

Biomed Res. 2008 Dec;29(6):271-8.

8.

Gene therapy with TRAIL against renal cell carcinoma.

Matsubara H, Mizutani Y, Hongo F, Nakanishi H, Kimura Y, Ushijima S, Kawauchi A, Tamura T, Sakata T, Miki T.

Mol Cancer Ther. 2006 Sep;5(9):2165-71.

9.
10.

Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.

Köpf-Maier P.

Anticancer Res. 1999 Jan-Feb;19(1A):493-504.

PMID:
10226588
11.

Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma.

Nakanishi H, Mizutani Y, Kawauchi A, Ukimura O, Shiraishi T, Hatano M, Mizuno M, Yoshida J, Miki T.

Clin Cancer Res. 2003 Mar;9(3):1129-35.

12.

A Src family inhibitor (PP1) potentiates tumor-suppressive effect of connexin 32 gene in renal cancer cells.

Fujimoto E, Sato H, Nagashima Y, Negishi E, Shirai S, Fukumoto K, Hagiwara H, Hagiwara K, Ueno K, Yano T.

Life Sci. 2005 Apr 22;76(23):2711-20. Epub 2005 Jan 28.

PMID:
15792837
13.

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4538-46.

14.

Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.

Loaiza-Pérez AI, Kenney S, Boswell J, Hollingshead M, Hose C, Linehan WM, Worrell R, Rubinstein L, Sausville EA, Vistica DT.

J Urol. 2004 Apr;171(4):1688-97.

PMID:
15017268
15.
16.
17.
18.

GTI-2040. Lorus Therapeutics.

Orr RM.

Curr Opin Investig Drugs. 2001 Oct;2(10):1462-6.

PMID:
11890366
19.

Verotoxin induces rapid elimination of human renal tumor xenografts in SCID mice.

Ishitoya S, Kurazono H, Nishiyama H, Nakamura E, Kamoto T, Habuchi T, Terai A, Ogawa O, Yamamoto S.

J Urol. 2004 Mar;171(3):1309-13.

PMID:
14767339
20.

Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas.

Kelly JD, Dai J, Eschwege P, Goldberg JS, Duggan BP, Williamson KE, Bander NH, Nanus DM.

Br J Cancer. 2004 Jul 5;91(1):164-70.

Supplemental Content

Support Center